Thursday, April 25, 2024
4/25/2024
¿ DESCRIPTION (provided by applicant): Bone metastatic prostate cancer is fatal and causes extensive pathological bone growth and destruction by manipulating osteoblasts and osteoclasts respectively. Understanding the factors driving the disease can help identify new therapeutic targets. Experimental approaches have dissected many of the molecular mechanisms involved but how factors at different scales collectively impact complex multi-cellular interactions over time is a significant challenge. Integrating molecular, cellular and clinical information into computational models offers a novel and powerful way to overcome this road-block: cell processes and mechanisms from different scales can be broken down into discrete and continuous components and used to parameterize a multi-scale model. This model can then be used to examine the temporal dynamics emerging from the multi scale cellular interactions. Rationale: Using our own and published data, we generated a novel computational model of normal bone remodeling controlled by TGFß and RANKL. Seeding the model with a metastatic prostate cancer cell generated in silico lesions that qualitatively and quantitatively mimic the pathophysiology of the human disease. As expected, our preliminary model confirmed the role of TGFß but predicted novel roles for cyclical osteoclast infiltration and mesenchymal stem cells in prostate cancer growth. Based on these emerging data, we believe that the enhancement of the computational model with cellular and molecular factors that control prostate cancer-bone interaction (PTHrP, Wnts, interleukins, chemokines and polarizing macrophages) will allow us to predict the key circuits driving the behavior of bone metastatic prostate cancer and to define new therapeutic strategies to treat this disease. We will test this hypothesis using the following integrated approaches: Approaches: In Aim 1, an enhanced molecular and cellular multiscale computational model will be developed and the key circuits driving bone metastatic cancer growth will be predicted. In Aim 2, we will predict the role of cyclical osteoclast infiltration and macrophage polarization (M1/M2) in promoting prostate cancer growth. Aim 3 will dissect the role of MSC recruitment in prostate cancer induced osteogenesis in silico. Importantly, the predictions generated in each aim will be tested with relevant in vivo rodent models of bone metastatic prostate cancer and validated in human clinical specimens. Quantitative biological values will be used to recalibrate the computational model in the event that outputs are discordant. Innovation/Impact: Our innovative studies will; 1) generate a robust and dynamic multi-scale computational model of the prostate cancer-bone microenvironment, 2) will define novel roles for monocyte derived cells (osteoclasts/M1/M2 macrophages) in driving prostate cancer growth, 3) will define new roles for MSCs in promoting prostate cancer induced osteogenesis, 4) will predict the key circuits driving bone metastatic prostate cancers and 5) will predict and test curative strategies for eradicating bone metastatic prostate cancer.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).
